Undisclosed soluble interleukin-17 receptor C therapeutics / EMD Serono - LARVOL DELTA

An Updated Analysis of PD1 and Immune Pathway Activity in Malignant Pediatric Central Nervous System (CNS) Tumors: A Pediatric Brain Tumor Consortium (PBTC) Study, PBTC-N13 (SNO 2025) - "HGG G1 pathways related to IL-17 signaling, NOD-like receptor signaling, and cytokine signaling, while G3 was enriched for PI3K-Akt signaling and ECM-receptor interaction. The addition of immune expression profiling in our study to PD-1/PD-L1 IHC scores enables better understanding of relevant immune-specific genes, with better characterization of noteworthy immune alterations that may aid in designing more effective immunotherapy for pediatric brain cancers."

Clinical • IO biomarker • Biliary Tract Cancer • Brain Cancer • CNS Tumor • Embryonal Tumor • Ependymoma • Glioma • High Grade Glioma • Medulloblastoma • Oncology • Pediatrics • Solid Tumor • EGFR • IL17A • PD-1 • PD-L1

An Updated Analysis of PD1 and Immune Pathway Activity in Malignant Pediatric Central Nervous System (CNS) Tumors: A Pediatric Brain Tumor Consortium (PBTC) Study, PBTC-N13 (SNO 2025) - "HGG G1 pathways related to IL-17 signaling, NOD-like receptor signaling, and cytokine signaling, while G3 was enriched for PI3K-Akt signaling and ECM-receptor interaction. The addition of immune expression profiling in our study to PD-1/PD-L1 IHC scores enables better understanding of relevant immune-specific genes, with better characterization of noteworthy immune alterations that may aid in designing more effective immunotherapy for pediatric brain cancers."

Clinical • IO biomarker • Biliary Tract Cancer • Brain Cancer • CNS Tumor • Embryonal Tumor • Ependymoma • Glioma • High Grade Glioma • Medulloblastoma • Oncology • Pediatrics • Solid Tumor • EGFR • IL17A • PD-1 • PD-L1

The TL1A-DR3 axis coordinates antigen presenting cell and IL17+ T cell crosstalk in HS (ISDS 2025) - "Tulisokibart, a monoclonal TL1A blocking antibody, has shown efficacy in Crohn's disease, reducing inflammatory cytokines and Th1 and Th17 pathways, in serum and intestinal biopsies, respectively. Multi-omic data suggests that the TL1A-DR3 axis mediates macrophage/DC crosstalk to T cells and may be involved in pro-inflammatory interactions between tissue cells (KC, fibroblasts) and immunopathogenic immune cells in HS."

Crohn's disease • Dermatology • Gastroenterology • Hidradenitis Suppurativa • Immunology • Inflammatory Bowel Disease • CD40 • CD40LG • IL17A • TNFA • TNFRSF25 • TNFSF15

An Updated Analysis of PD1 and Immune Pathway Activity in Malignant Pediatric Central Nervous System (CNS) Tumors: A Pediatric Brain Tumor Consortium (PBTC) Study, PBTC-N13 (WFNOS 2025) - "HGG G1 pathways related to IL-17 signaling, NOD-like receptor signaling, and cytokine signaling, while G3 was enriched for PI3K-Akt signaling and ECM-receptor interaction. The addition of immune expression profiling in our study to PD-1/PD-L1 IHC scores enables better understanding of relevant immune-specific genes, with better characterization of noteworthy immune alterations that may aid in designing more effective immunotherapy for pediatric brain cancers."

Clinical • IO biomarker • Biliary Tract Cancer • Brain Cancer • CNS Tumor • Embryonal Tumor • Ependymoma • Glioma • High Grade Glioma • Medulloblastoma • Oncology • Pediatrics • Solid Tumor • EGFR • IL17A • PD-1 • PD-L1

An Updated Analysis of PD1 and Immune Pathway Activity in Malignant Pediatric Central Nervous System (CNS) Tumors: A Pediatric Brain Tumor Consortium (PBTC) Study, PBTC-N13 (WFNOS 2025) - "HGG G1 pathways related to IL-17 signaling, NOD-like receptor signaling, and cytokine signaling, while G3 was enriched for PI3K-Akt signaling and ECM-receptor interaction. The addition of immune expression profiling in our study to PD-1/PD-L1 IHC scores enables better understanding of relevant immune-specific genes, with better characterization of noteworthy immune alterations that may aid in designing more effective immunotherapy for pediatric brain cancers."

Clinical • IO biomarker • Biliary Tract Cancer • Brain Cancer • Embryonal Tumor • Ependymoma • Glioma • High Grade Glioma • Medulloblastoma • Oncology • Pediatrics • Solid Tumor • EGFR • IL17A • PD-1 • PD-L1

A functional interleukin-4 homolog is encoded in the genome of infectious laryngotracheitis virus: Unveiling a novel virulence factor. (PubMed, PLoS Pathog) - "One such tactic involves acquiring functional copies of host genes encoding cytokines such as IL-6 (HHV-8), IL-10 (HHV-4, HHV-5), and IL-17 (SaHV-2)...In vivo bird studies demonstrated reduced pathogenicity of the vIL-4 knockout compared to wildtype. These results represent the first report of a previously unknown virokine encoded in the ILTV genome expressing a functional IL-4 homolog and virulence factor."

Journal • IL10 • IL17A • IL4 • IL6

Immunomonitoring in neoadjuvant pembrolizumab in combination with anthracycline versus carboplatin/paclitaxel containing chemotherapy regimens for the treatment of patients with early-stage, TIL-positive, triple-negative breast cancer (KeyPARTNER) (CIMT 2025) - "PBMC and TIL were tested for anti-cancer reactivity, defined by IFN-γ and IL-17 production against shared tumor-associated targets presented by classical and non-classical MHC molecules, e.g. MR1** or CD1...To date, 5/15 patients completed the treatment, with 4 cycles of CT+ICI followed by surgery – 2 from arm 1 (pembrolizumab [P] + CP: carboplatin + paclitaxel) and 3 from arm 2 (P + EC: epirubicin + cyclophosphamide)...Both AB TCR CD4+ and CD8+ TIL from patients receiving iCT neoadjuvant treatment showed increased frequency of CD39-CD69- (2/5) – a phenotype associated with improved responses in patients with melanoma receiving adoptive cell therapy. SCR and deep TCR sequencing are underway to test the anti-tumor specificity and the origin (lymph node, PBMC or tissue?) of TIL."

Clinical • Combination therapy • IO biomarker • Breast Cancer • Melanoma • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD4 • CD69 • CD8 • ENTPD1 • IFNG • IL17A

Drug Survival of Risankizumab vs Other Biologics After 13 Months of Treatment Among Patients with PsA in the Multicountry Postmarketing Observational VALUE Study (ACR Convergence 2023) - P | "Drug survival was compared for patients receiving RZB vs all other biologics, vs biologics excluding IL-23i, vs TNF-a inhibitors (TNFi), and vs IL-17 inhibitors (IL-17i). Patients with PsO and PsA who were treated with RZB in the real-world setting experienced fewer drug changes and a higher probability of drug survival compared with those treated with other biologic therapies. These results can help inform clinician decision making when initiating biologic treatment in patients with PsA. L."

Clinical • P4 data • Crohn's disease • Dermatology • Gastroenterology • Immunology • Inflammatory Bowel Disease • Psoriasis • Rheumatology • IL17A • IL23A

Inflammatory and Anti-Inflammatory Parameters in PCOS Patients Depending on Body Mass Index: A Case-Control Study. (PubMed, Biomedicines) - "Chronic low-grade inflammation is an independent factor affecting the occurrence of PCOS and does not depend on the presence of excess weight/obesity. For the first time, we obtained data on the increase in such inflammatory parameters as IL-9, MCP-3, and MIP-1α in women with PCOS."

Journal • Genetic Disorders • Obesity • Oncology • Polycystic Ovary Syndrome • CCL3 • CD40LG • CX3CL1 • IL12A • IL13 • IL15 • IL17A • IL18 • IL1A • IL2 • IL22 • IL4 • IL6 • IL9 • TNFA

Monoclonal anti-toxin therapy supports the protective innate immune response following Clostridioides difficile infection (P423) (IMMUNOLOGY 2023) - "Monoclonal antibodies (mAbs) that neutralize Toxin A and Toxin B, actoxumab and bezlotoxumab, respectively, significantly reduce disease severity in a murine model of C. difficile infection, however the impact of toxin neutralization on the induction of the innate immune response following infection is unknown...Further, no difference in neutrophil infiltration or production of IFNg or IL-17 from innate lymphoid cells (ILCs) was observed within the intestinal lamina propria following infection...Both IL-22+ ILCs and eosinophils promote protective host response following C. difficile infection. These findings indicate that activation of natural host protective mechanisms remain intact in the context of treatment that neutralizes toxin but does not alter C. difficile burden in the intestine."

Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • IFNG • IL17A • IL22

Pulmonary Application of Novel Antigen-Loaded Chitosan Nano-Particles Co-Administered with the Mucosal Adjuvant C-Di-AMP Resulted in Enhanced Immune Stimulation and Dose Sparing Capacity. (PubMed, Pharmaceutics) - "In addition, this vaccine formulation also promotes a strong Th1/Th17 response characterized by high secretion of IFN-γ, IL-2 and IL-17, as well as induction of CD8 T cells. Furthermore, the novel formulation exhibited strong dose-sparing capacity, enabling a 90% reduction of the antigen concentration. Altogether, our results suggest that chitosan nanocarriers, in combination with the mucosal adjuvant c-di-AMP, are a promising technology platform for the development of innovative mucosal vaccines against respiratory pathogens (e.g., Influenza or RSV) or for therapeutic vaccines."

Journal • Infectious Disease • Influenza • Respiratory Diseases • Respiratory Syncytial Virus Infections • CD8 • IFNG • IL17A

Andrographolide can potentially rescue unusable liver grafts by reducing fat content, enhancing mitochondrial function, and inhibiting Th1/Th17 immunity (EASL-ILC 2022) - "Cytokine levels in T cells including TNF-α, IFN-γ and IL-17 were Figure: (abstract: SAT315) measure using flow cytometry; qRT-PCR and ELISA (Human DuoSet ELISA, DY210/DY285B, RandD systems)... Andro is effective in reducing lipid content, promoting mitochondrial biogenesis and activating anti-oxidative system in hepatocytes. In addition, Andro inhibited Th1 and Th17 immunity. These results show that Andro has a great potential to rescue those marginal liver grafts to ease graft shortage in the setting of human liver transplantation."

Hepatology • Transplantation • IFNG • IL17A • NQO1 • TNFA

IL-23 maintains tissue resident memory Th17 cells in murine and psoriatic skin (ISDS 2021) - "Analysis of psoriasis skin from patients’ pre- and post-anti-IL-23 therapy revealed reduced numbers of IL-17-producing resident memory Th17 cells (TRM17) in skin post treatment...Thus, locally produced IL-23 promotes in situ proliferation of TRM17 and is required for their long-term retention in skin. Together with analysis of psoriasis patients, these results suggest that locally administered therapies targeting IL-23 may induce durable remission in psoriasis and other tissue-specific autoimmune diseases by depleting TRM17."

Preclinical • Dermatitis • Dermatology • Immunology • Infectious Disease • Inflammation • Psoriasis • CD301b • IL17A

[VIRTUAL] Inhibition of protein disulfide isomerase has neuroprotective effects in a mouse model of experimental autoimmune encephalomyelitis (MSDC 2020) - "The obtained lysates were used to measure IL-1β, IL-6, IL-17, IL-23, IFN-γ, and Bcl2 by commercially available ELISA kits...The significant differences between the two groups were calculated by the Student′s t-test or Mann-Whitney U test where appropriateResults Our observations suggested that CCF642 administration attenuates EAE clinical symptoms and the expression of ER stress-related proteins. Further, it suppressed the inflammatory infiltration of CD4 + T cells and the activation of hippocampus-resident microglia and Th17 cells.Conclusions We reported here that the inhibition of PDI protected EAE mice against neuronal apoptosis induced by prolonged ER stress and resulted in neuroprotection."

IO Biomarker • Preclinical • Behavior Disorders • CNS Disorders • Immunology • Inflammation • Mental Retardation • Multiple Sclerosis • Psychiatry • Solid Tumor • BCL2 • IFNG • IL17A • IL1B • IL6

Discovery of (3S,4R)-1-(1-(2-chloro-6-cyclopropylbenzoyl)-4-fluoro-1H-indazol-3-yl)-3-hydroxypiperidine-4-carboxylic acid as potent and selective allosteric inhibitors of RORγt for the treatment of autoimmune diseases (ACS-Fall 2017) - "Recent clinical success and FDA approval of anti-IL-17 antibody Secukinumab further validates the feasibility of this mechanism. In addition, we also showed that one tool molecule (compound A) demonstrated robust efficacy in a dose-dependent manner in a thymocyte PD model. In this poster, we will describe our optimization effort which led to the discovery of (3S,4R)-1-(1-(2-chloro-6-cyclopropylbenzoyl)-4-fluoro-1H-indazol-3-yl)-3-hydroxypiperidine-4-carboxylic acid (compound B) as a potent, selective RORgT allosteric inhibitor with improved pharmacokinetics and physiochemical properties."

Clinical • Biosimilar • Immunology

IL-17 in systemic lupus erythematosus (J Biomed Biotechnol) -

IL-17 increased production in patients with SLE can amplify the immune response by increasing target organ inflammation & damage & by augmenting production of antibodies by B cells

The correlation between serum MIF and IL-17、IL-23 in rheumatoid arthritis with atherosclerosis (EULAR 2011) - N=202; Serum MIF level in RA pts with AS group was significantly higher than that in NAS group & healthy controls, & it might be related with serum level of IL-17 & IL-23; Eelevated serum MIF level may be predictor for atherosclerosis in pts with RA

IL-23 is essential for the switching between Tfh-IFN-γ and Tfh-IL-17 in lupus (AAI 2019) - "Consistent with this, AdIL-23 administration suppressed the expression of Tbet, Ifng, Bcl6, Il21, Gata3, and Il4 but enhanced the expression Il17a, Il17f in Tfh cells. Our data suggest Tfh-IFN-γ and Tfh-IL-17 each plays an important role to determine the development of autoantibody producing B cells. While IL-23-mediated Tfh-IL-17 does not promote the size of autoreactive GCs, it regulates the induction of AID and thereby plays an important role to determine autoantibody affinity maturation"

IO Biomarker • PD(L)-1 Biomarker

Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis. (PubMed, J Manag Care Spec Pharm) - "Our findings suggest that initial targeted treatment with IL-17 inhibitors is the most effective treatment strategy for plaque psoriasis patients who have failed methotrexate and phototherapy. Apremilast, brodalumab, infliximab, ixekizumab, and secukinumab are cost-effective at different willingness-to-pay thresholds. Additional research is needed on whether the effectiveness of targeted agents changes when used after previously targeted agents."

HEOR • Journal